GLTx EndoC-βH5®
Model Type 2 Diabetes Glucolipotoxicity as Never Before
GLTx
EndoC-βH5®
Model Type 2 Diabetes Glucolipotoxicity as Never Before
PATHOPHYSIOLOGICAL RESPONSE TO GLUCOSE AND PALMITATE AGGRESSION
Unlock your beta-cell protection-mediated glucolipotoxicity drug discovery approach using a highly pathologically relevant human Type 2 Diabetes model
GLTx EndoC-βH5® is a specific version of the original human Endoc-BH5® beta cell line developed as a unique translational research tool dedicated to the study of glucolipotoxicity related to Human Type 2 diabetes. Glucolipotoxicity is a key element in Human Type 2 diabetes’ physiopathology combining the deleterious effects of elevated glucose and fatty acid levels on pancreatic β-cell function and survival. It impairs insulin secretion, inhibits insulin gene expression and induces β-cell death by apoptosis. Using a unique approach, GLTx EndoC-βH5® is a pharmacologically validated in vitro model of glucolipotoxicity, enabling researchers to obtain physiologically relevant data and accelerate drug discovery by recreating similar conditions as Human Type 2 diabetes glucolipotoxicity.
PATHOPHYSIOLOGICAL RESPONSE TO GLUCOSE AND PALMITATE AGGRESSION
Unlock your beta-cell protection-mediated glucolipotoxicity drug discovery approach using a highly pathologically relevant human Type 2 Diabetes model
GLTx EndoC-βH5® is a specific version of the original human Endoc-BH5® beta cell line developed as a unique translational research tool dedicated to the study of glucolipotoxicity related to Human Type 2 diabetes. Glucolipotoxicity is a key element in Human Type 2 diabetes’ physiopathology combining the deleterious effects of elevated glucose and fatty acid levels on pancreatic β-cell function and survival. It impairs insulin secretion, inhibits insulin gene expression and induces β-cell death by apoptosis. Using a unique approach, GLTx EndoC-βH5® is a pharmacologically validated in vitro model of glucolipotoxicity, enabling researchers to obtain physiologically relevant data and accelerate drug discovery by recreating similar conditions as Human Type 2 diabetes glucolipotoxicity.
FEATURES AND BENEFITS
A Pathophysiological Cell Model Recapitulating Human Type 2 Diabetes Glucolipotoxicity
GLTx EndoC-βH5® enables more accurate clinical predictions by modelling the response to glucose and lipid stress similar to that observed clinically. GLTx EndoC-βH5® robustly replicate beta cell dysfunction and death
A Pathophysiological Cell Model Recapitulating Human Type 2 Diabetes Glucolipotoxicity
GLTx EndoC-βH5® enables more accurate clinical predictions by modelling the response to glucose and lipid stress similar to that observed clinically. GLTx EndoC-βH5® robustly replicate beta cell dysfunction and death
DOWNLOADS
QUALITY ASSURANCE
Palmitate sensitivity tested
Viability
Functional validation (Glucose stimulated insulin secretion)
Negative for mycoplasma
APPLICATIONS
READOUT
CELL MODEL RELEVANCE
GLTx EndoC-βH5® Robustly Replicate Beta Cell Dysfunction and Death Induced by Glucolipotoxicity
NEED TO GO ONE STEP FURTHER?
Have questions, need more information, or looking for personalized assistance? Feel free to reach out to us directly. We are here to help you with any inquiries related to purchasing or product details.
